923565-21-3 Usage
Uses
Used in Pharmaceutical Industry:
GSK962040 is used as a treatment for type 2 diabetes and obesity due to its ability to stimulate the release of incretin hormones and promote glucose-dependent insulin secretion. This helps in improving blood sugar control and reducing insulin resistance in patients with these conditions.
Used in Metabolic Syndrome Management:
GSK962040 is used as a therapeutic agent for managing metabolic syndrome, a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes. Its beneficial effects on lipid metabolism, including increasing the release of peptide YY and reducing food intake, contribute to the overall management of this condition.
Used in Research and Development:
GSK962040 is used in ongoing research to explore its clinical applications and potential as a therapeutic agent for other related conditions. Further studies are being conducted to understand its mechanism of action, safety, and efficacy in treating various metabolic disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 923565-21-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,3,5,6 and 5 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 923565-21:
(8*9)+(7*2)+(6*3)+(5*5)+(4*6)+(3*5)+(2*2)+(1*1)=173
173 % 10 = 3
So 923565-21-3 is a valid CAS Registry Number.
923565-21-3Relevant articles and documents
Discovery of N-(3-fluorophenyl)-1-[(4-([(35)-3-methyl-1-piperazinyl]methyl) phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate
Westaway, Susan M.,Brown, Samantha L.,Fell, Stephen C. M.,Johnson, Christopher N.,MacPherson, David T.,Mitchell, Darren J.,Myatt, James W.,Stanway, Steven J.,Seal, Jon T.,Stemp, Geoffrey,Thompson, Mervyn,Lawless, Kirk,McKay, Fiona,Muir, Alison I.,Barford, Jonathan M.,Cluff, Chermaine,Mahmood, Sadhia R.,Matthews, Kim L.,Mohamed, Shiyam,Smith, Beverley,Stevens, Alexander J.,Bolton, Victoria J.,Jarvie, Emma M.,Sanger, Gareth J.
experimental part, p. 1180 - 1189 (2010/01/16)
N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl) acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.
